These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 30267281)

  • 1. Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.
    Johnson CM; Dassopoulos T
    Curr Gastroenterol Rep; 2018 Sep; 20(11):53. PubMed ID: 30267281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
    Hanauer SB; Sandborn WJ; Lichtenstein GR
    Gastroenterology; 2019 Jan; 156(1):36-42. PubMed ID: 30195449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?
    Ward MG; Irving PM; Sparrow MP
    World J Gastroenterol; 2015 Oct; 21(40):11331-42. PubMed ID: 26525434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role and advances of immunomodulator therapy for inflammatory bowel disease.
    Nielsen OH; Coskun M; Steenholdt C; Rogler G
    Expert Rev Gastroenterol Hepatol; 2015 Feb; 9(2):177-89. PubMed ID: 25101818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.
    Qiu Y; Mao R; Chen BL; Zhang SH; Guo J; He Y; Zeng ZR; Ben-Horin S; Chen MH
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1359-1372.e6. PubMed ID: 28232073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate in inflammatory bowel disease: A primer for gastroenterologists.
    AlAmeel T; Al Sulais E; Raine T
    Saudi J Gastroenterol; 2022; 28(4):250-260. PubMed ID: 35042318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimising use of thiopurines in inflammatory bowel disease.
    Dart RJ; Irving PM
    Expert Rev Clin Immunol; 2017 Sep; 13(9):877-888. PubMed ID: 28678626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When to Start Immunomodulators in Inflammatory Bowel Disease?
    Sharara AI
    Dig Dis; 2016; 34(1-2):125-31. PubMed ID: 26982809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there room for immunomodulators in ulcerative colitis?
    Chhibba T; Ma C
    Expert Opin Biol Ther; 2020 Apr; 20(4):379-390. PubMed ID: 31874578
    [No Abstract]   [Full Text] [Related]  

  • 12. Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease.
    Vasudevan A; Gibson PR; Van Langenberg DR
    Inflamm Bowel Dis; 2019 Aug; 25(9):1462-1473. PubMed ID: 30689858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.
    Xu Z; Davis HM; Zhou H
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S60-74. PubMed ID: 25707965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of thiopurines in inflammatory bowel disease.
    Frei P; Biedermann L; Nielsen OH; Rogler G
    World J Gastroenterol; 2013 Feb; 19(7):1040-8. PubMed ID: 23467510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance in inflammatory bowel diseases.
    Moreau J; Mas E
    Curr Opin Pharmacol; 2015 Dec; 25():56-61. PubMed ID: 26645664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminosalicylates, thiopurines and methotrexate in inflammatory bowel disease: Is it possible to discontinue the treatment?
    Sedano Muñoz R; Quera Pino R; Ibáñez Lazo P; Figueroa Corona C; Flores Pérez L
    Gastroenterol Hepatol; 2019 May; 42(5):339-347. PubMed ID: 30954317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of anti-drug antibodies against tumor necrosis factor inhibitors with addition of immunomodulators: A systematic review and meta-analysis.
    Dhindsa BS; Dhaliwal A; Mashiana HS; Saghir SM; Sayles H; Mubder M; Ohning G; Eichele D
    Indian J Gastroenterol; 2020 Apr; 39(2):153-160. PubMed ID: 32468382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
    Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
    World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Carman N; Mack DR; Benchimol EI
    Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.